Literature DB >> 3480372

Cancer in survivors of childhood soft tissue sarcoma and their relatives.

L C Strong1, M Stine, T L Norsted.   

Abstract

One hundred fifty-nine 3-year survivors of childhood soft tissue sarcoma and their relatives were surveyed to determine the frequency of second malignant neoplasms (SMNs) in patients and cancer in their relatives. The cancer experience of the patients, their offspring, siblings, parents, parental siblings, and grandparents was compared to that expected of the general population based on age-, sex- and calendar year-specific rates from the Connecticut Tumor Registry. A significant excess of SMNs was observed in the patients (observed expected = 8:0.38). Among 758 first-degree relatives, a significant cancer excess was observed (34:20.68), attributable largely to cancer of soft tissue and bone (6:0.44) and breast (9:3.39) and to cancers occurring before age 35 years (12:4.14). Overall, a significantly lower than expected cancer incidence was confirmed in the 1,693 second-degree relatives (142:178). To identify patient characteristics associated with higher than expected familial cancer risk, kindreds were partitioned by patient age at diagnosis tumor type, tumor site SMN and other factors. A highly significant cancer excess was observed in the relatives of SMN patients (26:12.78). The tumor types occurring in excess in close relatives were also observed as SMNs in the patients. The findings confirm an association among childhood soft tissue sarcoma and cancers of the breast, bone, joint, or soft tissue as SMN in patients and in close relatives and suggest that the risk of a second tumor is associated with a familial predisposition to cancer.

Entities:  

Mesh:

Year:  1987        PMID: 3480372

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  30 in total

1.  Individual-specific liability groups in genetic linkage, with applications to kindreds with Li-Fraumeni syndrome.

Authors:  Sanjay Shete; Christopher I Amos; Shih-Jen Hwang; Louise C Strong
Journal:  Am J Hum Genet       Date:  2002-01-30       Impact factor: 11.025

Review 2.  Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

3.  Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome.

Authors:  Barry W Brown; Tracy J Costello; Shih-Jen Hwang; Louise C Strong
Journal:  Hum Genet       Date:  2005-11-12       Impact factor: 4.132

Review 4.  The current state of oncogenes and cancer: experimental approaches for analyzing oncogenetic events in human cancer.

Authors:  P J Chiao; F Z Bischoff; L C Strong; M A Tainsky
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

5.  The human MyoD1 (MYF3) gene maps on the short arm of chromosome 11 but is not associated with the WAGR locus or the region for the Beckwith-Wiedemann syndrome.

Authors:  M Gessler; H Hameister; I Henry; C Junien; T Braun; H H Arnold
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

6.  Low incidence of familial breast cancer among Hispanic women.

Authors:  M L Bondy; M R Spitz; S Halabi; J J Fueger; V G Vogel
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

7.  Family history of cancer and seizures in young children with brain tumors: a report from the Childrens Cancer Group (United States and Canada).

Authors:  R R Kuijten; S S Strom; L B Rorke; C P Boesel; J D Buckley; A T Meadows; G R Bunin
Journal:  Cancer Causes Control       Date:  1993-09       Impact factor: 2.506

Review 8.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

9.  Childhood predictive genetic testing for Li-Fraumeni syndrome.

Authors:  D G Evans; P Lunt; T Clancy; R Eeles
Journal:  Fam Cancer       Date:  2009-04-30       Impact factor: 2.375

10.  A novel genetic modifier of p53, mop1, results in embryonic lethality.

Authors:  Susan C Evans; Min Liang; Christopher Amos; Xiangjun Gu; Guillermina Lozano
Journal:  Mamm Genome       Date:  2004-06       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.